Back to discover
Drug

Elotuzumab

Approved · EMA
ClassSLAM family member 7 inhibitorEmerging researchLate-stage developmentRising momentum

Also known as Empliciti.

RxNorm1726104ChEMBLCHEMBL1743010ATCL01FX08UNII1351PE5UGS
3
Research papers
19
Active clinical trials
SLAM family member 7
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom

Clinical trial2026-07-30Status changed to Active, not recruiting · ClinicalTrials.gov

A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Clinical trial2026-07-09Results expected Q3 2026 · ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Clinical trial2026-07-07Results expected Q4 2027 · ClinicalTrials.gov

Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma

Clinical trial2026-06-25Results expected Q2 2031 · ClinicalTrials.gov

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Clinical trial2026-06-23Results expected Q4 2028 · ClinicalTrials.gov

A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Patients With Myelofibrosis

Clinical trial2026-06-11Results expected Q4 2027 · ClinicalTrials.gov

Phase 1b Study to Assess Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Clinical trial2026-05-13Results expected Q4 2026 · ClinicalTrials.gov

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Clinical trial2026-05-04Results expected Q2 2027 · ClinicalTrials.gov

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.

Research2023-04-07Clinical lymphoma, myeloma & leukemia

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Research2018-08-10Frontiers in immunology

Accelerated approval: Empliciti (EMA)

Regulatory2016-05-11EMA

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Research2015-06-02The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Elotuzumab
Aliases & brands
Empliciti
RxNorm CUI
1726104
ChEMBL ID
CHEMBL1743010
ATC codes
L01FX08
UNII
1351PE5UGS
Primary mechanism
SLAM family member 7 inhibitor
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

SLAM family member 7
SLAMF7 · Q9NQ25
INHIBITORSLAM family member 7 inhibitor

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2016-05-11
Latest approval
2016-05-11
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2016-05-11Accelerated approval
Accelerated approval: Empliciti (EMA)
Indication: Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see… Show full indication

Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

60 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
60
registered trials across all phases
LATEST COMPLETION 2026
19
Active studies
6
Recruiting
14
Late-stage (III+)
26
Completed
15
Discontinued
PHASE DISTRIBUTIONn = 60
Early Phase 11Phase 17Phase 1 / 26Phase 232Phase 314

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

RecruitingPH IIIRegeneron Pharmaceuticalsn=4102033

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

RecruitingPH IIIHoffmann-La Rochen=3802033

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM

WithdrawnPH IIICelgene2030

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM

Active, not recruitingPH IIIWuerzburg University Hospitaln=5762029

A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruitingPH IIIEuropean Myeloma Network B.V.n=1172029

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

CompletedPH IIICelgenen=3862026

Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab

CompletedPH IIBristol-Myers Squibbn=672026

Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

CompletedPH IIUniversity of Chicagon=462025

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

CompletedPH I/IISWOG Cancer Research Networkn=1422025

LCI-HEM-MYE-CRD-002: A Phase II Study of Carfilzomib- Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

CompletedPH IIWake Forest University Health Sciencesn=152025

Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody Therapy

CompletedPH IIMayo Clinicn=372024

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20152023
Major research themes3
COVID-191Immunotherapy, Adoptive1Multiple Myeloma1
Journals, researchers & institutions
Top journals
  • Clinical lymphoma, myeloma & leukemia1
  • Frontiers in immunology1
  • The New England journal of medicine1
Leading researchers
  • Anderson KC2
  • Atrash S1
  • Beksac M1
  • Belch A1
  • Bhutani M1
  • Bleickardt E1
  • Cho SF1
  • Dimopoulos M1
Leading institutions
free-text, unnormalised
  • Clinical Trials1
  • College of Medicine1
  • From Winship Cancer Institute1
  • Harvard Medical School1
  • Hematology Oncology Research Laboratory1
  • Immune Monitoring Core Laboratory1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Approved indications
Multiple Myeloma2

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Daratumumab

Studied across the same disease area as Elotuzumab in the shared literature.

1 shared disease1 shared paper
Dexamethasone

Studied across the same disease area as Elotuzumab in the shared literature.

1 shared disease1 shared paper
Lenalidomide

Studied across the same disease area as Elotuzumab in the shared literature.

1 shared disease1 shared paper
Thalidomide

Studied across the same disease area as Elotuzumab in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.